PharmaShots | Incisive News in 3 Shots

Subscribe Now

severe eosinophilic asthma

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

October 4, 2019

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

September 30, 2019

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yr...

September 13, 2019

AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

September 18, 2018

GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma

GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma

September 11, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us